Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series
Hair loss appears to be an underreported side effect of IVGT post-TURBT. Patients should be counseled about this potential adverse event prior to treatment, and routine inquiry regarding alopecia should be considered in those undergoing IVGT post-TURBT. Prospective multicenter studies are encouraged to better evaluate the incidence and risk factors associated with this adverse event.
Authors
- K. Chamie
- Domenique Escobar (ORCID: https://orcid.org/0000-0002-2712-3663)
- Gina M. Badalato
- S. Daneshmand
- Anne Schuckman
- Piyush K. Agarwal (ORCID: https://orcid.org/0000-0002-6042-6834)
- S. Lerner
- Anosh Dadabhoy (ORCID: https://orcid.org/0009-0003-1578-4901)
- Sanam Ladi-Seyedian
- Chirag Doshi (ORCID: https://orcid.org/0000-0001-5416-4746)
- Mazyar Zahir
- Max Kates
- Alon Weizer
- Leilei Xia
Institutions
- University of Southern California (US)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Baylor College of Medicine (US)
- University of Chicago (US)
- Mount Sinai Medical Center (US)
- Columbia University (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1016/j.urolonc.2025.12.020
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00